155 results
Page 4 of 8
8-K
EX-99.1
t4jgfxo47k qp2nqjmoj
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
1tdh9k
15 Dec 21
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
7:00am
8-K
EX-99.1
lhr59s bk2yrqg
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
ryk008wf31sidmq
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-99.1
myd40
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-3.2
xl3dgqbx2rpg9n1zt
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-99.1
un70q7jg9isi8weyn
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-2.1
lgijr8 2qbetvig3
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
u1nplhv w4
14 Sep 21
Regulation FD Disclosure
4:20pm
424B5
s113b6epn
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-99.1
x4lujinq
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
p5rg jl6x643e5x
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
mdjmgxatxtzo
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
onwu7o
27 May 21
Regulation FD Disclosure
7:01am
424B3
9rgfvp
30 Apr 21
Prospectus supplement
5:01pm